The antibiotic resistance crisis is one of the most pressing challenges facing global healthcare. Without effective action, routine procedures, cancer treatments and even minor infections could once again become life-threatening.
The UK, Europe and the broader international community are grappling with this reality and solutions that bridge the gap between pharmaceutical innovation and public health are urgently needed.
A critical obstacle to solving this crisis is the broken economic model for antibiotics. Despite the high medical need, the market incentives to develop new antibiotics are fundamentally flawed.
Check out the rest of the feature here
